Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. - Test2 - elhamkhani - TriplyDB

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

http://www.wikidata.org/entity/Q33597579

about

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis ISG56 and IFITM1 proteins inhibit hepatitis C virus replication Ribavirin: Past, present and future Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians Using high-throughput genomics to study hepatitis C: What determines the outcome of infection?The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations Influence of host resistance on viral adaptation: hepatitis C virus as a case study Gene expression signature-based screening identifies new broadly effective influenza a antivirals Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection STAT1 pathway mediates amplification of metastatic potential and resistance to therapy Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.Ribavirin improves early responses to peginterferon through improved interferon signaling Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse An interferon response gene signature is associated with the therapeutic response of hepatitis C patients Current and future therapies for hepatitis C virus infection.Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Predicting the probable outcome of treatment in HCV patients.S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response Hepatitis C virus virology and new treatment targets.Single cell analysis of HCV-infected patient hepatocytes: the science is no longer science fiction

P2860

Q21132564-D7344C4D-5C93-4ECA-9449-6B1BD2B9AEB6 Q24339446-7F752B7A-1E8C-44A0-9A7B-7360129996E4 Q26775002-270A9430-E0C5-4744-95A0-9CE9374E611D Q26784252-49EA3BDC-0A94-496B-A169-0A7D8B6622D3 Q27488260-D92387E5-F687-4D66-AC58-F90C20BA9399 Q27488407-2B4160D0-AD38-4573-8E2D-A35655441CF5 Q27489040-96D510E0-AD4D-4FCB-A7CE-CF86F707F679 Q27490650-9AB662BC-5E3B-42DD-87EB-7051E79AB344 Q28072953-9E517C83-675D-447C-A6B7-79F4122D9175 Q28087595-73603A77-9309-4E2D-8631-E8D6BE5EE458 Q28475681-D41630D8-397C-4EA8-9B6A-A50B953005D9 Q28478142-6AA8D9D6-B505-4ADA-8F8F-9CD568E8B428 Q28483978-1B58114B-D51B-4CB5-B1C2-20C4EC508D94 Q28534715-232B42E2-6045-40A3-9D50-B54FDF661DB8 Q29615959-35CD3A17-1E28-45B2-8A5A-CC57D28E2986 Q33463332-D8FA1CAA-997C-4C65-9E00-FCCC6501728E Q33599325-07B1FE26-4F3D-4E4F-A926-8E7ADED2C589 Q33726212-C9D415B9-E069-43D6-BC80-4843AE58F283 Q33745372-DD82FB15-1F46-43C2-8EFE-5E17B759E3EA Q33816657-4305F305-9102-4A41-82E2-273A6543C558 Q33822643-64FF6191-0CBA-4143-BBD0-89695917B40B Q33944295-1109071C-2393-42B9-9A32-FE7DC5E1176C Q33987120-1F0A254A-6061-4C16-B6AF-EB045D319473 Q34009002-0346039B-361E-4A5D-BEED-3258A8D475EE Q34027569-CDFFD6C7-60B5-4BB5-9038-F0FDB1E61BC2 Q34036762-B74D91A8-DEDA-45E5-9F1B-DB81C37BFBE8 Q34082923-68C05CF4-6733-4F13-A1A7-489CF9AD95CD Q34105079-0A99ADBD-0118-41F1-B522-7953B466E388 Q34142463-2BCA07F5-113F-4721-AC6E-6E8C93B20152 Q34163327-9094169F-9888-4CDA-A8BF-E48858CA1B5A Q34409020-4902DFD6-94DF-487A-B036-B7CEAAF0665F Q34409039-1CCADFB4-90BC-44E3-B0D7-735CEAF95114 Q34493348-6606CFD6-F7C0-4FB9-9AAE-50E1B80F032E Q34497983-24FA68DF-2DE4-49BE-B765-5D6B6EEF5578 Q34593704-A0EF5DAE-1B9F-47BC-A39B-60272C9877A7 Q34714349-3140AACF-267E-4973-96F9-AFB5371FAFDC Q34750577-CB63A2C0-C99C-497F-99F5-B81E67610469 Q34867045-32A53F42-95A5-4C87-A820-95A0D13F844D Q34974042-B8D098CB-C37D-4941-9444-D0095D2452DD Q35029683-B636CE0C-CA7D-4395-B96B-ABD02F373155

P2860

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

http://www.wikidata.org/entity/Q33597579

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Hepatic gene expression during ...... thways for treatment response.

@ast

Hepatic gene expression during ...... thways for treatment response.

@en

type

label

Hepatic gene expression during ...... thways for treatment response.

@ast

Hepatic gene expression during ...... thways for treatment response.

@en

prefLabel

Hepatic gene expression during ...... thways for treatment response.

@ast

Hepatic gene expression during ...... thways for treatment response.

@en

P1433

Q33597579-8A0CDFF1-3AB3-4312-9972-F12B4D3D932C

P1476

Q33597579-5E7A7875-A864-4AA9-885C-2E1358681B28

P2093

Q33597579-11AA0522-33A8-433A-9871-1C5F75AB8762

Q33597579-13283AB9-5B13-4DE5-8CD4-CE92CB4608C8

Q33597579-24DB2280-C3A8-471D-A162-7A9245C5C657

Q33597579-5F254BAB-F965-4A83-96D7-E16E2192DEA8

Q33597579-78C7A54B-3F85-4621-9CC5-773FCF63F72A

Q33597579-9FD51CD0-6DC8-432C-8C85-7C6597D0E32D

Q33597579-A9A66CEF-468B-4574-93B6-6ED5321BCFF1

Q33597579-B4FDE333-B0B9-40EC-90B2-9655179A00F7

Q33597579-D2BC2B10-C575-455B-BD82-95E81700687A

Q33597579-D4685C6B-F9CB-405D-9B71-FC64A382690F

P2860

Q33597579-0406C4B8-D142-4FD9-843F-23061E378349

Q33597579-04E2FA33-0824-44D4-BE13-B93CEF6CE598

Q33597579-0728286E-662B-475E-B2C0-0773F78D6EA4

Q33597579-09C1DD65-F416-4201-BC9D-D1ADFA04F324

Q33597579-0A055827-DB03-4BD9-A37D-B2420992E6D5

Q33597579-251FEEE1-39F2-43CF-9392-FEF659F30529

Q33597579-2DF9083B-0B82-4115-8513-7106045869AB

Q33597579-35903EDB-506B-4D05-B366-7DA28BD5AC1B

Q33597579-36500ED7-F1AA-47E2-82DB-135BF09C56BB

Q33597579-42DBB98D-81CB-4393-B7B1-081F1F214D7C

P304

Q33597579-6E04D609-A823-4983-BA1C-E8FC567C6089

P31

Q33597579-20FC299F-0428-44D4-A7DB-10DE2ACB0A16

P356

Q33597579-68B39E60-103B-4F4A-A4F4-EAE38C003ABA

P407

Q33597579-6EAD2342-23DE-424E-A36E-9BF267281745

P433

Q33597579-A974BBA5-A772-4C80-9ED9-8EA15C9EEBCB

P478

Q33597579-154A8F2E-6ECF-4021-8EE0-4DAB895D9481

P577

Q33597579-7FF00AF1-8E30-4120-BF96-A54B93CAB85C

P5875

Q33597579-AA184A66-1BEF-450F-A9FD-E99BD72B0545

P698

Q33597579-6F06671E-DCA8-442A-A5B7-2582E5E1A3E6

P932

Q33597579-022BCEE3-5825-4A23-AE04-6E8B4FA1634E

P356

P1433

P1476

Hepatic gene expression during ...... thways for treatment response.

@en

P2093

Dickens Theodore

http://www.w3.org/2001/XMLSchema#string

Jordan J Feld

http://www.w3.org/2001/XMLSchema#string

Lisa M Schweigler

http://www.w3.org/2001/XMLSchema#string

Maggie Cam

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Santosh Nanda

http://www.w3.org/2001/XMLSchema#string

Steven L Zacks

http://www.w3.org/2001/XMLSchema#string

Susan N Pusek

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

Weiping Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector

Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C

Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

Analysis of Affymetrix GeneChip data using amplified RNA.

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.

P304

1548-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.21853

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5916522

http://www.w3.org/2001/XMLSchema#string

P698

17929300

http://www.w3.org/2001/XMLSchema#string

P932

2808168

http://www.w3.org/2001/XMLSchema#string